Intellia Therapeutics price to sales ratio NTLA

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 26.4×
8-year median: 44.8×
Against its 8-year history: 35th; percentile: 0 is its lowest day, 100 its highest
8-year range: 13.4× to 188×
Peer median: 6.9×

Intellia Therapeutics' price to sales ratio is 26.4× as of Oct 23, 2026.

That is below its 8-year median of 44.8×, lower than on 65% of days in the last 8 years.

Over that time it ranged from 13.4× in Mar 2020 to 188× in Jul 2021.

The median for 7 diagnostics and research stocks of a similar size is 6.9×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	26.4×	21.6×	37.1×
2025	n/m a value too high to mean anything
2024	43.8×	38.5×	60.6×
2023	52.7×	38.6×	74.0×
2022	53.4×	53.4×	172×
2021	188×	59.4×	188×
2020	51.6×	13.4×	58.9×
2019	18.8×	14.4×	27.4×

Against its peers

Companies in Medical - Diagnostics & Research nearest Intellia Therapeutics' size, closest first, today.

Company	Price to sales ratio
NTLAIntellia Therapeutics	26.4×
CDNACareDx	7.8×
VCYTVeracyte	6.9×
BLLNBillionToOne	12.8×
NRCNRC Health	3.5×
LNTHLantheus	4.2×
CAICaris Life Sciences	9.1×
BIOBio-Rad Laboratories	3.8×
Peer median	6.9×

Where Intellia Therapeutics ranks

#58of 61Diagnostics and research stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Intellia Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.